Cargando…

Improved Quantification of (18)F-FDG PET during (131)I-Rituximab Therapy on Mouse Lymphoma Models after (131)I Prompt Emission Correction

(18)F-FDG Positron Emission Tomography (PET) is used to monitor tumor response to (131)I-therapy, but is confounded by prompt emissions (284, 364, 637, and 723 keV) from (131)I, particularly in animal PET imaging. We propose a method for correcting this emission in (18)F-FDG PET. The (131)I prompt e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Young Sub, Kim, Hee-Joung, Kim, Jin Su
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6963650/ https://www.ncbi.nlm.nih.gov/pubmed/31597334 http://dx.doi.org/10.3390/diagnostics9040144

Ejemplares similares

The role of (18)F-FDG PET/CT in patients with diffuse large B-cell lymphoma after radioimmunotherapy using (131)I-rituximab as consolidation therapy
por: Choi, Joon Ho, et al.
Publicado: (2022)

(131)I–Tositumomab in lymphoma
por: Cheung, M.C., et al.
Publicado: (2009)

Standard Operating Procedure for In-house Preparation of (131)I-rituximab for Radioimmunotherapy of Non-Hodgkin's Lymphoma
por: Pickford, Matthew D., et al.
Publicado: (2012)

Predicting (131)I-avidity of metastases from differentiated thyroid cancer using (18)F-FDG PET/CT in postoperative patients with elevated thyroglobulin
por: Liu, Min, et al.
Publicado: (2018)

Standard Operating Procedure for Prospective Individualised Dosimetry for ([131])I-rituximab Radioimmunotherapy of Non-Hodgkin's Lymphoma
por: Calais, Phillipe J., et al.
Publicado: (2012)

Value of (18)F-FDG Hybrid PET/MR in Differentiated Thyroid Cancer Patients with Negative (131)I Whole-Body Scan and Elevated Thyroglobulin Levels
por: Li, Hongyan, et al.
Publicado: (2021)

Impact of (18)F-FDG PET/CT on treatment of patients with differentiated thyroid carcinoma, negative (131)I whole body scan and elevated serum thyroglobulin
por: Boktor, Raef R., et al.
Publicado: (2022)

Prognostic Role of 2-[(18)F]FDG PET/CT Metabolic Volume Parameters in Patients Affected by Differentiated Thyroid Carcinoma with High Thyroglobulin Level, Negative (131)I WBS and Positive 2-[(18)F]-FDG PET/CT
por: Albano, Domenico, et al.
Publicado: (2021)

Radioiodination and Purification of [(131)I]β-CIT and [(131)I]FP-CIT with an Automated Radiosynthesizer
por: Plhak, Elisabeth, et al.
Publicado: (2022)

FDG PET Predicts the Effects of (131)I and Prognosis for Patients with Bone Metastases from Differentiated Thyroid Carcinoma
por: Wang, Danyang, et al.
Publicado: (2020)

Incremental diagnostic value of [(18)F]tetrafluoroborate PET-CT compared to [(131)I]iodine scintigraphy in recurrent differentiated thyroid cancer
por: Dittmann, Matthias, et al.
Publicado: (2020)

Precise preoperative diagnosis of struma ovarii with pseudo-Meigs’ syndrome mimicking ovarian cancer with the combination of (131)I scintigraphy and (18)F–FDG PET: case report and review of the literature
por: Fujiwara, Sayaka, et al.
Publicado: (2018)

Diagnostic Performance of (18)F-FDG PET/CT in Papillary Thyroid Carcinoma with Negative (131)I-WBS at first Postablation, Negative Tg and Progressively Increased TgAb Level
por: Qiu, Zhong-Ling, et al.
Publicado: (2017)

Optimizing reconstruction parameters for quantitative (124)I-PET in the presence of therapeutic doses of (131)I
por: Fanchon, Louise M., et al.
Publicado: (2021)

(131)I-metaiodobenzylguanidine ((131)I-MIBG) therapy for residual neuroblastoma: a mono-institutional experience with 43 patients
por: Garaventa, A, et al.
Publicado: (1999)

Predictive value of LN metastasis detected by (18)F-FDG PET/CT in patients with papillary thyroid cancer receiving iodine-131 radiotherapy
por: Li, Chao, et al.
Publicado: (2019)

The role of Tg kinetics in predicting 2-[(18)F]-FDG PET/CT results and overall survival in patients affected by differentiated thyroid carcinoma with detectable Tg and negative 131I-scan
por: Albano, Domenico, et al.
Publicado: (2021)

Findings of I-131 SPECT/CT, (18)F-FDG, and (68)Ga-FAPI-04 PET/CT Imaging in a Patient Treated with Radioiodine Therapy for Metastatic Papillary Thyroid Carcinoma
por: Tatar, Gamze, et al.
Publicado: (2023)

I-131 uptake in fat necrosis of the breast
por: Itani, Malak, et al.
Publicado: (2016)

Both F-18 FDG-avidity and Malignant Shape of Cervical Lymph Nodes on PET/CT after Total Thyroidectomy Predict Resistance to High-dose I-131 Therapy in Patients with Papillary Thyroid Cancer
por: Byun, Byung Hyun, et al.
Publicado: (2013)

Toxicity of upfront (131)I-metaiodobenzylguanidine ((131)I-MIBG) therapy in newly diagnosed neuroblastoma patients: a retrospective analysis
por: Bleeker, Gitta, et al.
Publicado: (2013)

(131)I-Caerin 1.1 and (131)I-Caerin 1.9 for the treatment of non-small-cell lung cancer
por: Liu, Na, et al.
Publicado: (2022)

The influence of thionamides on intra-thyroidal uptake of (131)I during radioiodine-131 treatment of Graves’ disease
por: Happel, Christian, et al.
Publicado: (2023)

Interventional therapy for human breast cancer in nude mice with (131)I gelatin microspheres ((131)I-GMSs) following intratumoral injection
por: Li, Chuan-Chao, et al.
Publicado: (2014)

Development of [(131)I]I-EOE-TPZ and [(131)I]I-EOE-TPZMO: Novel Tirapazamine (TPZ)-Based Radioiodinated Pharmaceuticals for Application in Theranostic Management of Hypoxia
por: Elsaidi, Hassan, et al.
Publicado: (2019)

Apoptosis gene reprograming of human peripheral blood mononuclear cells induced by radioiodine-131 ((131)I) irradiation
por: Li, Jian-Fang, et al.
Publicado: (2019)

Induction of Leukaemia by (131)I Treatment of Thyroid Carcinoma
por: Brincker, H., et al.
Publicado: (1973)

Biodistribution of (131)I in mice is influenced by circadian variations
por: Andersson, Charlotte K., et al.
Publicado: (2020)

MON-437 False Positive I-131 Uptake
por: Yadav, Pavan Rajendra, et al.
Publicado: (2020)

Nodular hepatocellular carcinoma--treatment with intraarterial injection of I-131 Lipiodol.
por: Yoo, H. S., et al.
Publicado: (1990)

Inhibition of HIF-1α by Atorvastatin During (131)I-RTX Therapy in Burkitt’s Lymphoma Model
por: Kim, Eun-Ho, et al.
Publicado: (2020)

Dosimetric analysis of (123)I, (125)I and (131)I in thyroid follicle models
por: Josefsson, Anders, et al.
Publicado: (2014)

Calibration of Traceable Solid Mock (131)I Phantoms Used in an International SPECT Image Quantification Comparison
por: Zimmerman, BE, et al.
Publicado: (2013)

Renal Metastasis and Dual ((18)F-Fluorodeoxyglucose and (131)I) Avid Skeletal Metastasis in a Patient with Papillary Thyroid Cancer
por: Kulkarni, Prashanth, et al.
Publicado: (2017)

Evaluation of the specificity of [(18)F]fludarabine PET/CT in a xenograft model of follicular lymphoma: comparison with [(18)F]FDG and impact of rituximab therapy
por: Hovhannisyan, Narinée, et al.
Publicado: (2015)

Follicular thyroid carcinoma metastasizing to rare sites and exhibiting variable inter-lesional heterogeneity on (18)F-fluorodeoxyglucose positron emission tomography/computed tomography and (131)I
por: Parghane, Rahul V., et al.
Publicado: (2020)

The use of 131I-MIBG in the imaging of metastatic carcinoid tumours.
por: Jodrell, D. I., et al.
Publicado: (1988)

Sequelae and survivorship in patients treated with (131)I-MIBG therapy
por: Sze, W C C, et al.
Publicado: (2013)

Unexpected Uptake by the Gallbladder in Post-Ablative I-131 Scan
por: Ünal, Kemal, et al.
Publicado: (2015)

Inguinal Endometriosis Visualized on I-131 Whole Body Scan
por: Çayır, Derya, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_h7j6njb3ogqkn82lb6p2jpq3ht